Glaukos (NYSE:GKOS) Hits New 1-Year High on Better-Than-Expected Earnings

Key Points

• Glaukos exceeded quarterly expectations: Revenue rose 58% year over year to $211.03 million, while adjusted EPS reached $0.47 versus analysts’ expected loss of $0.10. The strong report pushed shares to a new 52-week high.
• Management raised its growth outlook: The company increased 2026 revenue guidance to $775 million–$785 million and set a preliminary 2027 sales target of approximately $1 billion, driven by momentum in iDose TR and Epioxa.
• Analyst sentiment is broadly positive, but insider selling is a risk to monitor: Several firms raised price targets and maintained Buy ratings, while insiders sold roughly 83,000 shares worth $15 million in the latest quarter.

Glaukos Corporation (NYSE:GKOS - Get Free Report) shares hit a new 52-week high on Thursday following a better than expected earnings announcement. The company traded as high as $229.27 and last traded at $232.6050, with a volume of 941,122 shares trading hands. The stock had previously closed at $181.43.

The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.57. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. During the same period last year, the firm posted ($0.16) EPS. The company's revenue for the quarter was up 58.0% on a year-over-year basis.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record growth and profitability: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the $168 million analyst consensus. Glaukos reported adjusted EPS of $0.47 versus expectations for a $0.10 loss, while GAAP results showed $2 million in net income, or $0.03 per diluted share, compared with a loss in the prior-year quarter. Glaukos Q3 earnings and revenue report
• Positive Sentiment: Higher sales outlook: Management raised 2026 revenue guidance to $775 million-$785 million from $680 million-$700 million and introduced a preliminary 2027 sales target of approximately $1 billion. The outlook reflects continued momentum in the company’s glaucoma and corneal-health franchises, including iDose TR and Epioxa. Glaukos strong Q3 results and higher sales outlook
• Positive Sentiment: Analysts raised targets and ratings: Needham lifted its target to $251, BTIG raised its target to $234, and Stifel increased its target to $225; all three firms now rate GKOS “Buy.” The new targets imply meaningful upside from the stock’s recent trading level. Needham analyst ratings
• Positive Sentiment: Healthy financial position: Glaukos generated $14.8 million in operating cash flow and ended the quarter with $162.3 million in cash, supporting continued investment in product development and commercialization.
• Neutral Sentiment: The earnings call and financial releases will be closely watched for additional details on adoption, reimbursement, and the pace at which iDose TR and Epioxa can support the ambitious 2027 sales target. Glaukos Q3 earnings call transcript
• Negative Sentiment: Quiver data shows 32 open-market insider sales and no purchases over the past six months, including selling by senior executives. While such transactions may reflect compensation or diversification, the pattern is a potential secondary concern for investors.

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of analyst reports. UBS Group began coverage on Glaukos in a research report on Tuesday, July 28th. They set a "neutral" rating and a $150.00 price objective for the company. Truist Financial set a $255.00 price target on shares of Glaukos in a research report on Thursday. HC Wainwright increased their price objective on shares of Glaukos from $168.00 to $195.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Citigroup reissued a "buy" rating on shares of Glaukos in a research note on Thursday. Finally, Wall Street Zen upgraded shares of Glaukos from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $201.57.

Insider Activity

In other news, Director Leana Wen sold 525 shares of Glaukos stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $167.63, for a total value of $88,005.75. Following the transaction, the director directly owned 21,092 shares in the company, valued at approximately $3,535,651.96. The trade was a 2.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 60,000 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the transaction, the chief operating officer owned 72,588 shares of the company's stock, valued at approximately $13,046,967.12. The trade was a 45.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 83,025 shares of company stock valued at $14,950,006 in the last quarter. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Glaukos

Large investors have recently modified their holdings of the stock. Allworth Financial LP bought a new position in Glaukos during the 2nd quarter worth about $28,000. CoreCap Advisors LLC acquired a new position in shares of Glaukos during the third quarter worth about $33,000. Fortitude Family Office LLC bought a new position in shares of Glaukos during the third quarter worth about $36,000. Parallel Advisors LLC grew its holdings in shares of Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 226 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of Glaukos by 523.4% during the second quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier's stock worth $41,000 after buying an additional 246 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Performance

The stock has a 50-day moving average of $171.24 and a 200-day moving average of $139.87. The firm has a market cap of $13.58 billion, a price-to-earnings ratio of -70.02 and a beta of 0.69. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company's principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.